Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | CHIEF LEGAL OFFICER | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,012 |
Ending reported balance
After 2026-05-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-05-18 · Exercise / conversion · Acquired 2,454 · Balance 136,890 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-05-18 · Tax withholding · Disposed 881 · Balance 136,009 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-05-18 · Exercise / conversion · Acquired 5,156 · Balance 141,165 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-05-18 · Tax withholding · Disposed 1,850 · Balance 139,315 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-05-18 · Exercise / conversion · Acquired 7,250 · Balance 146,565 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-05-18 · Tax withholding · Disposed 2,602 · Balance 143,963 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-05-18 · Exercise / conversion · Acquired 9,435 · Balance 153,398 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-05-18 · Tax withholding · Disposed 3,386 · Balance 150,012 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,280 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Exercise / conversion · Disposed 2,454 · Balance 12,280 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,728 |
Reported balance
After 2026-05-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-18 · Exercise / conversion · Disposed 5,156 · Balance 56,728 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 123,262 |
Reported balance
After 2026-05-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-18 · Exercise / conversion · Disposed 7,250 · Balance 123,262 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 217,018 |
Reported balance
After 2026-05-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-18 · Exercise / conversion · Disposed 9,435 · Balance 217,018 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · derivative · entry 12 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,763 Underlying: Common Stock · 7,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · derivative · entry 11 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,667 Underlying: Common Stock · 5,156 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · derivative · entry 10 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,004 Underlying: Common Stock · 2,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · derivative · entry 9 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,378 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,824 | $2.69 | $7,596.56 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 8 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,673 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 7 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,009 | $2.69 | $5,404.21 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 6 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,247 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,156 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 5 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 956 | $2.69 | $2,571.64 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,100 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $2.69 | $2,114.34 |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,602 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013980 · form4-05212025_090505.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 10,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007891 · form4-03122025_090346.xml · derivative · entry 6 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,823 Underlying: Common Stock · 10,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007891 · form4-03122025_090346.xml · derivative · entry 5 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,458 Underlying: Common Stock · 4,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 4,017 | $4.36 | $17,514.12 |
DisclosureSEC source: 0001415889-25-007891 · form4-03122025_090346.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,372 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 10,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007891 · form4-03122025_090346.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,912 | $4.36 | $8,336.32 |
DisclosureSEC source: 0001415889-25-007891 · form4-03122025_090346.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,076 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007891 · form4-03122025_090346.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 174,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007279 · form4-03062025_100358.xml · derivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,013 Underlying: Common Stock · 174,013 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 275,735 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001415889-25-007279 · form4-03062025_100358.xml · derivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,735 Underlying: Common Stock · 275,735 shares Expires 2035-03-04 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 4, 2025 and each month thereafter until fully vested. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004928 · form4-02202025_110252.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $5.31 | $4,173.66 |
DisclosureSEC source: 0001415889-25-004928 · form4-02202025_110252.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,080 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004928 · form4-02202025_110252.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · derivative · entry 9 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,136 Underlying: Common Stock · 7,735 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · derivative · entry 8 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,366 Underlying: Common Stock · 3,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · derivative · entry 7 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,410 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,603 | $6.03 | $15,696.09 |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · nonDerivative · entry 6 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,850 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · nonDerivative · entry 5 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,235 | $6.03 | $7,447.05 |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,718 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 661 | $6.03 | $3,985.83 |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,272 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027368 · form4-11202024_111121.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · derivative · entry 9 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,871 Underlying: Common Stock · 7,735 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · derivative · entry 8 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,047 Underlying: Common Stock · 3,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · derivative · entry 7 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,426 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,826 | $5.53 | $15,627.78 |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · nonDerivative · entry 6 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,917 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · nonDerivative · entry 5 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,434 | $5.53 | $7,930.02 |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,008 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $5.53 | $4,346.58 |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,761 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021860 · form4-08212024_100843.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 3,487 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · derivative · entry 9 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,606 Underlying: Common Stock · 5,156 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · derivative · entry 8 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,728 Underlying: Common Stock · 2,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · derivative · entry 7 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,442 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,009 | $5.96 | $11,973.64 |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · nonDerivative · entry 6 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,044 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,156 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · nonDerivative · entry 5 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 956 | $5.96 | $5,697.76 |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,897 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $5.96 | $4,684.56 |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,399 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014145 · form4-05222024_100555.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.